Drugmaker says it could have potential coronavirus treatment ready by end of summer


Regeneron Pharmaceuticals is still conducting trials on its double-antibody cocktail for COVID-19, but the company will have a head start on distribution should the Food and Drug Administration grant an emergency use authorization for the potential treatment.
Regeneron on Tuesday said the U.S. government signed a $450 million dollar contract with the company to make and supply the cocktail — which consists of two human antibodies binding "non-competitively to the receptor binding domain of the virus' spike protein" hindering its ability "to escape treatment" — as part of "Operation Warp Speed," the initiative aimed at accelerating the development of and access to coronavirus vaccines and treatments during the pandemic.
Pending FDA approval, Regeneron said it expects somewhere between 70,000 and 300,000 treatment doses or 420,000 to 1.3 million prevention doses, with the initial batch ready to go as early as the end of the summer. If that's the case, the government has reportedly committed to making the doses available to Americans at no cost and would be responsible for their distribution. Read more at CNBC.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
What to know before turning to AI for financial advice
the explainer It can help you crunch the numbers — but it might also pocket your data
-
Book reviews: 'The Headache: The Science of a Most Confounding Affliction—and a Search for Relief' and 'Tonight in Jungleland: The Making of Born to Run'
Feature The search for a headache cure and revisiting Springsteen's 'Born to Run' album on its 50th anniversary
-
Keith McNally' 6 favorite books that have ambitious characters
Feature The London-born restaurateur recommends works by Leo Tolstoy, John le Carré, and more
-
Texas declares end to measles outbreak
Speed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agency
Speed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Measles cases surge to 33-year high
Speed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC